secwatch.observer — SEC 8-K summary
======================================

Issuer:     Forte Biosciences, Inc. (FBRX)
CIK:        0001419041
Form:       8-K
Filed at:   2022-06-02T23:59:59+00:00
Accession:  0001193125-22-166208
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Forte Biosciences shareholders elect two Class II directors, ratify auditor, approve equity plan
--------------------------------------------------------------------------------

- Steven Kornfeld elected Class II director with 3,366,874 votes for; Patricia Walker with 3,335,739 for, 1,612,841 withheld; 3,373,670 broker non-votes.
- Ratification of Mayer Hoffman McCann as independent auditor for FY2022: 8,107,698 for, 157,062 against, 57,490 abstentions.
- Increase to 2021 Equity Incentive Plan approved: 2,826,803 for, 2,106,190 against, 15,587 abstentions, 3,373,670 broker non-votes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1419041/000119312522166208/0001193125-22-166208-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1419041/000119312522166208/d348649d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-166208

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer